Overview

Clarithromycin in Multiple Myeloma Induction Therapy

Status:
Terminated
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This study evaluates the potential synergic anti-myeloma activity of clarithromycin when combined with VCD induction therapy in patients with newly diagnosed multiple myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
Henrik Gregersen
Collaborator:
Danish Myeloma Study Group
Treatments:
Clarithromycin